| Company announcement | Orphazyme A/S |
| No. 13/2017 | Ole Maaløes Vej 3 |
| DK-2200 Copenhagen N | |
| www.orphazyme.com | |
| Company Registration No. 32266355 | |
| 21 November 2017 |
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 ("Orphazyme"), hereby notifies receipt of information regarding the following grants under Orphazyme's long-term incentive programme as further described in company announcement 8/2017:
| 1 | Details of the Reporting Person / Closely Associated Person | ||
| a) | Name | Anders Hinsby | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Executive Officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Orphazyme A/S | |
| b) | LEI code | 54930025OZD2GGSQ7L42 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Rights to acquire or subscribe for matching shares and performance shares in Orphazyme A/S ISIN DK0060910917 | |
| b) | Nature of the transaction | Grant of rights (subject to certain conditions) to acquire or subscribe for matching shares and performance shares under Orphazyme A/S' long-term incentive programme | |
| c) | Price(s) and volume(s) | Price (s) | Volume(s) |
| 0 | 5,000 (Matching shares) | ||
| 0 | 30,000 (Performance shares assuming full vesting) | ||
| d) | Aggregated information Aggregated volume Price | ||
| e) | Date of the transaction | 2017-11-21 17:00 UTC+1 | |
| f) | Place of the transaction | Outside a trading venue | |
| 1 | Details of the Reporting Person / Closely Associated Person | ||
| a) | Name | Anders Vadsholt | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Financial Officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Orphazyme A/S | |
| b) | LEI code | 54930025OZD2GGSQ7L42 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Rights to acquire or subscribe for matching shares and performance shares in Orphazyme A/S ISIN DK0060910917 | |
| b) | Nature of the transaction | Grant of rights (subject to certain conditions) to acquire or subscribe for matching shares and performance shares under Orphazyme A/S' long-term incentive programme | |
| c) | Price(s) and volume(s) | Price (s) | Volume(s) |
| 0 | 4,000 (Matching shares) | ||
| 0 | 16,000 (Performance shares assuming full vesting) | ||
| d) | Aggregated information Aggregated volume Price | ||
| e) | Date of the transaction | 2017-11-21 17:00 UTC+1 | |
| f) | Place of the transaction | Outside a trading venue | |
| 1 | Details of the Reporting Person / Closely Associated Person | ||
| a) | Name | Thomas Kirkegaard Jensen | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Scientific Officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Orphazyme A/S | |
| b) | LEI code | 54930025OZD2GGSQ7L42 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Rights to acquire or subscribe for matching shares and performance shares in Orphazyme A/S ISIN DK0060910917 | |
| b) | Nature of the transaction | Grant of rights (subject to certain conditions) to acquire or subscribe for matching shares and performance shares under Orphazyme A/S' long-term incentive programme | |
| c) | Price(s) and volume(s) | Price (s) | Volume(s) |
| 0 | 4,000 (Matching shares) | ||
| 0 | 16,000 (Performance shares assuming full vesting) | ||
| d) | Aggregated information Aggregated volume Price | ||
| e) | Date of the transaction | 2017-11-21 17:00 UTC+1 | |
| f) | Place of the transaction | Outside a trading venue | |
| 1 | Details of the Reporting Person / Closely Associated Person | ||
| a) | Name | Thomas Blaettler | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Medical Officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Orphazyme A/S | |
| b) | LEI code | 54930025OZD2GGSQ7L42 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Rights to acquire or subscribe for matching shares and performance shares in Orphazyme A/S ISIN DK0060910917 | |
| b) | Nature of the transaction | Grant of rights (subject to certain conditions) to acquire or subscribe for matching shares and performance shares under Orphazyme A/S' long-term incentive programme | |
| c) | Price(s) and volume(s) | Price (s) | Volume(s) |
| 0 | 1,875 (Matching shares) | ||
| 0 | 7,500 (Performance shares assuming full vesting) | ||
| d) | Aggregated information Aggregated volume Price | ||
| e) | Date of the transaction | 2017-11-21 17:00 UTC+1 | |
| f) | Place of the transaction | Outside a trading venue | |
For additional information, please contact
Orphazyme
Anders Vadsholt, CFO +45 28 98 90 55
Attachments:http://www.globenewswire.com/NewsRoom/AttachmentNg/6b37567d-5422-4aa7-81d2-413e41a23b35
